Back to search results

89Zr-Panitumumab for Head and Neck Cancer Metastasis

This study is looking at how well a special imaging agent, 89Zr-panitumumab, can find suspected metastatic lesions (cancer that has spread) in people with head and neck squamous cell carcinoma (HNSCC). You might be able to join if you are at least 19 years old, have a confirmed diagnosis of HNSCC, and have had a recent standard PET/CT scan that shows possible metastatic lesions. The study will give you a small amount of 89Zr-panitumumab intravenously (into a vein) before your regular diagnostic tests. Researchers will compare how well 89Zr-panitumumab and your standard PET/CT scan identify these lesions. The goal is to see if 89Zr-panitumumab can accurately detect these lesions. The study is currently recruiting about 60 participants.

Study design
This is an interventional study, meaning participants will receive a study intervention. It plans to enroll 60 participants.
What's involved
Participants will receive a bolus of 89Zr-panitumumab intravenously. This will happen before further standard diagnostic evaluation of their lesions.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 1 year to measure the sensitivity and specificity of 89Zr-panitumumab.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05423197

89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC

Withdrawn
PHASE2Ages 19+InterventionalDiagnostic
Andrei Iagaru
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:89Zr-panitumumab IVPanitumumab

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity and Specificity of 89Zr-panitumumab
Measured over Up to 1 year

Conditions

Head-and-neck Squamous Cell Carcinoma

Explore related trials

Head and Neck Squamous Cell Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Fred Baik, MD · PRINCIPAL_INVESTIGATOR · Stanford Cancer Institute

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 19 years.
Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.
Subjects diagnosed with any T stage, any subsite within the head and neck. Subjects with recurrent disease or a new primary will be allowed.
Must have standard of care 18F-FDG-PET/CT scan ≤ 30 days of Day 0 with suspected metastatic lesions.
Have acceptable hematological status, coagulation status, kidney function, and liver function including the following clinical results:
Hemoglobin ≥ 9gm/dL
White blood cell count \> 3000/mm3
Platelet count ≥ 100,000/mm3
Serum creatinine ≤ 1.5 times upper reference range
PTT = 11.5 - 14.4 seconds
INR = 0.9 - 1.2

Exclusion

Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
History of infusion reactions to other monoclonal antibody therapies
Pregnant or breastfeeding
Magnesium or potassium lower than the normal institutional values
Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
Severe renal disease or anuria
Known hypersensitivity to deferoxamine or any of its components

What this trial measures

  • Sensitivity and Specificity of 89Zr-panitumumabUp to 1 year

    The total number of head and neck squamous cell carcinoma-involved incidental lesions will be determined and correlated to the radiologically suspicious lesions identified by 89Zr-panitumumab using PET/CT imaging.